{
    "clinical_study": {
        "@rank": "127846", 
        "arm_group": [
            {
                "arm_group_label": "RXI-109", 
                "arm_group_type": "Experimental", 
                "description": "Treatment with RXI-109 on one side of revised scar and a placebo comparator on the other side.  Treatment to begin either immediately or 2 weeks following the scar revision surgery."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Treatment with RXI-109 on one side of revised scar and a placebo comparator on the other side.  Treatment to begin either immediately or 2 weeks following the scar revision surgery."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the effectiveness of RXI-109 in reducing the\n      recurrence of hypertrophic scar formation following elective revision of a pre-existing\n      hypertrophic abdominal scar."
        }, 
        "brief_title": "A Study to Evaluate the Effectiveness and Safety of RXI 109 on the Outcome of Scar Revision Surgery in Healthy Adults", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Hypertrophic Scar", 
        "condition_browse": {
            "mesh_term": [
                "Hypertrophy", 
                "Cicatrix, Hypertrophic", 
                "Cicatrix"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adults, 21-55 years of age in general good health\n\n          -  Previous partial hysterectomy, Cesarean section or abdominoplasty surgery resulting\n             in a transverse hypertrophic scar of \u2265 11 cm in length\n\n          -  Scar to be revised must have been present for >1 year\n\n        Exclusion Criteria:\n\n          -  Use of tobacco or nicotine-containing products\n\n          -  Pregnant or lactating\n\n          -  Post-menopausal or full hysterectomy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "32", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 6, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02030275", 
            "org_study_id": "RXI-109-1301"
        }, 
        "intervention": [
            {
                "arm_group_label": "RXI-109", 
                "description": "Intradermal administration on one side of revised scar and a placebo comparator on the other side.  Treatment to begin either immediately or 2 weeks following the scar revision surgery.", 
                "intervention_name": "RXI-109", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Intradermal administration on one side of revised scar and a placebo comparator on the other side.  Treatment to begin either immediately or 2 weeks following the scar revision surgery.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Hypertrophic scar", 
            "Cicatrix", 
            "Scar prevention", 
            "Scar revision"
        ], 
        "lastchanged_date": "April 21, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Lake Worth", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33461"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Louis", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63141"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Huntersville", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "28078"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mountlake Terrace", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98043"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multi-Center, Prospective, Randomized, Double-Blind, Within-Subject Controlled, Phase 2a Study to Evaluate the Effectiveness and Safety of RXI 109 on the Outcome of Scar Revision Surgery on Transverse Hypertrophic Scars on the Lower Abdomen Resulting From Previous Surgeries in Healthy Adults", 
        "overall_contact": {
            "email": "clinicaloperations@rxipharma.com", 
            "last_name": "Manager, Clinical Operations"
        }, 
        "overall_official": {
            "affiliation": "RXi Pharmaceuticals", 
            "last_name": "Pamela Pavco, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To evaluate the effectiveness of RXI-109 in reducing the recurrence of hypertrophic scar formation following elective revision of a hypertrophic abdominal scar", 
            "measure": "Reduction in recurrence of hypertrophic scarring after scar revision surgery", 
            "safety_issue": "No", 
            "time_frame": "9 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02030275"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "To assess severity and frequency of reported adverse events and clinically-relevant changes in laboratory testing after elective revision of a hypertrophic abdominal scar", 
            "measure": "Safety of RXI-109", 
            "safety_issue": "Yes", 
            "time_frame": "9 months"
        }, 
        "source": "RXi Pharmaceuticals, Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "RXi Pharmaceuticals, Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}